On the contrary, the percentage of CD14+CD16+SLAN− intermediate monocytes was significantly higher in CLL patients, at (median; IQR) 5.18 (3.62–8.30%) as compared to 4.05 (2.96–5.48%) in healthy volunteers (p < 0.01) (Figure 2B). The gene discussed is FCGR3A; the disease is B-cell chronic lymphocytic leukemia.